Company
Recursion Pharmaceuticals
Recursion Pharmaceuticals uses artificial intelligence and automated laboratory systems to accelerate drug discovery and development. The company operates an AI-native platform that combines physical automation with machine learning to identify and advance potential treatments for oncology, rare diseases, and other conditions with high unmet medical need. Recursion has multiple drug candidates in clinical trials and partners with pharmaceutical and technology companies to expand its drug discovery capabilities.
Recursion Pharmaceuticals is a publicly traded company operating in the biotech & pharma sector, based in USA. It trades on the Nasdaq under the ticker RXRX. Leadership tracked by CEOInsider includes Chris Gibson (CEO).
Leadership
Current
Recent developments
AI summary of recent coverageRecent coverage has focused on Recursion Pharmaceuticals' significant leadership transition, with founder and long-time CEO Chris Gibson stepping down after twelve years to be succeeded by Najat Khan, a veteran from Johnson & Johnson. The shift reflects broader industry pressure on the company to move beyond earlier hype surrounding artificial intelligence-driven drug development and demonstrate concrete clinical results. Following the transition, Gibson has since joined a venture capital firm while remaining affiliated with Recursion as an advisor through mid-2026.
Summarized from the headlines in the sidebar; see each source for the full story.